Clinical Trials | December 08, 2025
Pfizer’s therapy scores major win in Phase 3 trial for Hemophilia patients with inhibitors
HYMPAVZI’s safety profile was generally favorable
HYMPAVZI’s safety profile was generally favorable
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Relmada expects to initiate its Phase 3 program in the first half of 2026
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
Subscribe To Our Newsletter & Stay Updated
